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P.J. M E I E R-A BT
Science and innovation have always been important pillars of the social, cultural and economic development of Switzerland. Th is is especially true for biomedical research, a fi eld in which this small country has a long and successful tradition. Indeed, it is probably not an overstatement to say that Switzerland's current wealth and high standard of living would not have been possible without a continuous fl ow of biomedical discoveries and new life science technologies, together with their successful translation into medical practice.
Th is progress is surprising for such a small country as Switzerland. It is based on several factors including the stable and free political system, the periodic appearance of outstanding intellectual personalities and the creation of an increasing number of academic institutions over the past few centuries.
Some of the most creative and infl uential Swiss personalities to push forward biomedical research are featured in this issue of the Karger Gazette. Certainly many other individuals and innovations of equal importance could have been added, but the examples selected highlight a broad spectrum of Swiss contributions. Included are pioneering molecular studies (the discovery of DNA), groundbreaking progress in psychiatry (the concept of 'schizophrenia'), the development of surgical techniques and tools, innovative synthetic chemistry (the industrial synthesis of vitamin C), and the fi rst steps into the area of nutritional health with the propagation of Bircher muesli. Th is issue also ventures into more controversial territory with a look at Ita Wegman, who founded anthroposophical medicine in Switzerland. Although the scientifi c basis of this system of healthcare remains a matter of debate, complementary and alternative medicine has become very popular and remains a huge challenge for the rational application of the principles of evidenced-based medicine.
It is important to remember that these outstanding individuals did not exist in splendid isolation. Th ey were immersed in a culture that had for centuries stimulated research, through the consecutive foundation of fi ve universities (Basel, Bern, Geneva, Lausanne, Zürich) and two Federal Schools of Technology (ETH Zürich and Lausanne). Th e oldest of these is the University of Basel, which was founded by Papal decree in 1460 and is celebrating its 550th anniversary this year.
During its long existence the University of Basel has hosted many infl uential and visionary thinkers. Among those to walk the halls of the university are Erasmus, the humanist and theologian, the famous Bernoulli family of mathematicians, Friedrich Nietzsche, the philosopher, and Carl Gustav Jung, the psychiatrist. Today, the region of Basel is one of the world's leading life science centers, hosting the headquarters of pharmaceutical giants Novartis and Roche alongside numerous other drug companies and research institutions. In this, Basel has profi ted greatly from its strategic location at the point where the borders of France and Germany meet Switzerland.
Although somewhat younger of age, the other Swiss universities also declared biomedical sciences as one of their priorities and gained international reputations in various research fi elds. Today, attempts are being made to bundle and coordinate tertiary education and sciences within a nationwide network of complementary research groups and strong interactions between the diff erent Swiss universities.1
Th ese developments refl ect a trend in modern science away from individual researchers and towards research teams. Indeed, it is a debated issue whether the future of scientifi c research will be driven by outstanding single individuals, as in the past, or by teams and centers of closely interacting researchers and organizations. But it is certain that the times of Friedrich Miescher, who made his breakthrough discovery of DNA working alone in a converted kitchen, are behind us.
The Power of We
Great ideas springing from the great minds of singularly creative individuals will always remain a force of the utmost potency, These developments refl ect a trend in Th modern science away from individual researchers and towards research teams. Indeed, it is a debated issue whether the future of scientifi c research will fi be driven by outstanding single individuals, as in the past, or by teams and centers of closely interacting researchers and organizations. But it is certain that the times of Friedrich Miescher, who made his breakthrough discovery of DNA working alone in a converted kitchen, are behind us.
The P Power T of We Great ideas springing from the great minds of singularly creative individuals will always remain a force of the utmost potency, age becaus e our cultura l evoluti on by far outpac es biologi cal evoluti on. Howev er, I think such a distinc tion betwee n 'pure' senescen ce and patholo gical age-ass ociated process es is a rather academ ic issue, raising unnece ssary barrier s betwee n basic and applied geronto logical researc h that may impair the crucial and benefic ial dialogue betwee n various discipl ines. In addition, we should not forget that geronto logy in a broade r sense encom passes many fields outside of biology , the aging society represe nting one of the most import ant socioec onomic problem s facing not only the develop ed world, but increas ingly also the less develop ed countr ies.
Age-Re lated Diseas es: The Price for the Vigor of Youth
In 1900, the mean life expect ancy in Central Europe and the USA was about 49 years. Since that time, life expecta ncy has increas ed more than in the 10,000 years before. This has been due to advanc es in medici ne and hygien e, as well as improv ements in socioec onomic conditi ons.
Althou gh the mean life expecta ncy has increas ed, this has been associa ted with a rather constan t value for maxim ally attainable age. When plotted on a graph, this leads to a 'rectan gulariz ation' of the human surviva l curve (Fig. 1, page 2 ). This observ ation is one of many indicat ions that the aging process is govern ed by both genetic and environ mental factors . Discus sing this issue in depth is beyond the scope of this article. Suffice it to mentio n that different species exhibit differe nt maxim al lifespa ns that show a signific ant correlation with their capacit y to repair DNA damag e. 
